IN BRIEF

This article reviews the history of phlorizin, the role of the kidney in glucose regulation, and the modulation of that regulatory system via pharmacological means. It also offers a discussion of the results of clinical trials of the most salient sodium glucose co-transporter inhibitor to date: dapagliflozin.

 

No Comments »

No comments yet.

RSS feed for comments on this post.

Leave a comment